Investigating the Role of Mucin and Mucin Glycosylating Enzymes in Nasopharyngeal Carcinoma and Salivary Gland Cancer and Their Correlation With Clinical Prognosis

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02401763

Enrollment

200

Registered

2015-03-30

Start date

2015-04-30

Completion date

Unknown

Last updated

2015-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nasopharyngeal Carcinoma, Salivary Gland Cancer

Keywords

biomarker

Brief summary

Nasopharyngeal carcinoma (NPC) is the tenth leading cancers in Taiwan and investigating its biomarker is important for understanding the mechanism of its pathogenesis.

Detailed description

NPC is the tenth leading cancers in Taiwan and investigating its biomarker is important for understanding the mechanism of its pathogenesis.

Interventions

None listed

Study design

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

20 Years to 80 Years

Healthy volunteers

Inclusion criteria

* NPC and salivary gland tumor diagnosed and treated in HTUH

Exclusion criteria

* previous treatment or surgery

Design outcomes

Primary

Measure	Time frame
The difference of expression level of mucin glycosylating enzymes (by immunohistochemistry) in nasopharyngeal carcinoma and salivary gland tissues	1~5 years after patients received definite therapy

Contacts

Primary ContactMei-Chun Lin, MD

mayandjean@gmail.com886-972-654-470

Backup ContactPei-Jen Lou, MD, PhD

pjlou@ntu.edu.tw

Outcome results